Joint radionuclide therapy and immunotherapy approach. The combination shows promising therapeutic option for prostate cancer patients.
Read full article >>
Other news & events
- News04.08.2026
Virtual Radiotheranostics Summit: Expanding Access to Targeted Cancer Care Across Africa
Read more - News29.07.2026
TerraPower Isotopes Collaborates with Oncidium Foundation to Donate Actinium-225, Expanding Cancer Treatment Access
Read more - News01.07.2026
Türkiye Introduces Reimbursement for Actinium-225 PSMA Therapy
Read more
